Cancer-fighting antibodies with a one-two punch take aim at tumours

Two antibodies are better than one. That is the premise behind a new class of cancer-fighting antibodies that are engineered to attack tumours from two angles at once. These bispecific antibodies are designed to boost the body's immune response by simultaneously targeting cancer cells and activating immune cells. The approach is showing promise in treating B-cell lymphoma and other cancers. The new antibodies are engineered to bind to two different targets.

One target is a protein on the surface of cancer cells. The other is a protein on the surface of immune cells called macrophages. By binding to both targets, the antibodies bring the macrophages close to the cancer cells, making it easier for the macrophages to kill the cancer cells. This dual-action mechanism is a significant departure from traditional antibody therapies, which typically target only one protein on cancer cells. The development of these bispecific antibodies is part of a broader trend in cancer research towards more precise and targeted therapies.

The approach has the potential to improve outcomes for patients with a wide range of cancers. According to Nature, the new antibodies are already being tested in clinical trials. BioSpectrum Asia notes that the third dimension of antibody therapy is opening up new possibilities for precision medicine. Futura, le média qui explore le monde, describes the breakthrough as rewriting hope for hundreds of diseases.